Company Overview: FOXO Technologies Inc.

Business Focus:
FOXO Technologies Inc. is a healthcare services and technology company engaged in the development, commercialization, and delivery of epigenetic biomarker technology and healthcare services. It operates across two main segments: Healthcare and Labs and Life.

Business Segments and Operations

1. Healthcare Segment

• Core Operations:

  • Owns and operates a rural hospital (Scott County Community Hospital, doing business as Big South Fork Medical Center, BSF) in Oneida, Tennessee, with 25 inpatient beds and a 24/7 emergency department.
  • Owns Myrtle Recovery Centers, Inc., providing behavioral health services focusing on substance use disorder treatments, including inpatient, residential detoxification, residential rehabilitation, and outpatient services.
  • Acquired Rennova Community Health, Inc. (RCHI) and its wholly owned subsidiary SCCH, a critical access hospital in East Tennessee, also with 25 inpatient beds and ancillary services such as laboratory, radiology, respiratory, and pharmacy.

• Facilities & Locations:

  • 1 hospital in Oneida, Tennessee (BSF)
  • Myrtle’s rehabilitation and detoxification facilities in Tennessee
  • RCHI’s hospital (SCCH) in East Tennessee

• Services:

  • Hospital inpatient and emergency care
  • Substance use disorder treatments (residential and outpatient)
  • Ancillary services: laboratory, radiology, respiratory, pharmacy

• Employees:

  • Not explicitly specified for healthcare operations, but the overall company had 168 employees as of March 31, 2025, with 102 full-time.

2. Labs and Life Segment

• Core Operations:

  • Commercializes proprietary epigenetic biomarker technology aimed at research and risk classification.
  • Develops saliva-based epigenetic tests that provide health, wellness, and aging insights traditionally measured through blood and urine.
  • Uses machine learning and AI for data analysis and biomarker discovery.
  • Products include epigenetic tests for life insurance underwriting, wellness, and longevity.

• Research & R&D:

  • Focused on discovering and validating epigenetic biomarkers for health assessment and aging.
  • Currently paused on sales and further product development of the “Underwriting Report” and “Longevity Report” due to cash constraints but continues research.

• Revenues:

  • Recognizes revenue from epigenetic testing services and royalties (e.g., from Illumina for array sales).
  • Previously derived residual commissions from legacy life insurance agency operations.

Financial Highlights (as of the Latest Data)

• Revenue:

  • $4.05 million for the year ended December 31, 2024
  • $145,291 for the year ended December 31, 2023

• Employees:

  • 168 employees as of March 31, 2025 (102 full-time, none unionized)

• Net Income / Loss:

  • Net loss attributable to FOXO in 2024: $12.4 million
  • Net loss attributable to FOXO in 2023: $26.5 million
  • The company has a history of losses and expects continued net losses.

• Assets & Capital:

  • Cash and cash equivalents as of December 31, 2024: $68,268
  • Working capital deficit as of December 31, 2024: $29.8 million
  • The company has experienced significant impairment charges and has substantial debt, with ongoing funding needs.

Strategy and Developments

• Acquired Myrtle Recovery Centers in June 2024 and RCHI in September 2024 to expand healthcare services.
• Operating and developing epigenetic biomarker technology for health and longevity applications—focusing on research, bioinformatics, and consumer wellness testing.
• Cancelled plans to launch a life insurance subsidiary due to market and regulatory conditions, sold FOXO Life Insurance Company in early 2023.
• Engaged in multiple financings, private placements, and convertible notes to fund operations amid ongoing losses.
• Focus on commercializing epigenetics-based health and wellness tools, research, and data analysis solutions rather than insurance underwriting.

In summary:
FOXO Technologies Inc. is a healthcare and biotech firm that owns hospitals providing emergency and substance use treatment, runs behavioral health centers, and develops saliva-based epigenetic diagnostics and biomarkers. It leverages machine learning and AI to discover biomarkers related to health, aging, and wellness, targeting scientific research and consumer health insights. The company has recurring revenue from lab testing and royalties, but it is currently operating at a net loss with significant debt and limited cash reserves.